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Abstract
Purpose Cyclosporine A (CsA) is the most widely used immunosuppressive agent after a hematopoietic stem cell transplantation
(HSCT). Although recommendations for CsA dose conversion from intravenous to oral administration differ from 1:1 to 1:3,
most studies did not consider the role of azole antifungals as an important confounder. Therefore, we assess the optimal
conversion rate of CsA from intravenous to oral administration in HSCT recipients, taking into account the concomitant use
of azole antifungals.
Methods We retrospectively included patients from a large database of 483 patients who underwent a HSCT and received
intravenous CsA as part of the conditioning regimen and peritransplant immunosuppression. All patients were converted from
intravenous to oral administration in a 1:1 conversion rate. We collected for each patient three CsA trough concentrations during
intravenous and oral administration, directly before and after conversion to oral administration.
Results We included 71 patients; 50 patients co-treated with fluconazole, 10 with voriconazole, and 11 without azole co-
medication. In patients with voriconazole, the dose-corrected CsA concentration (CsA concentration divided by CsA dosage)
was not different between intravenous and oral administration (2.6% difference, p = 0.754), suggesting a CsA oral bioavailability
of nearly 100%. In patients with fluconazole and without azole co-medication, the dose-corrected CsA concentration was
respectively 21.5% (p < 0.001) and 25.2% (p = 0.069) lower during oral administration.
Conclusions In patients with voriconazole, CsA should be converted 1:1 from intravenous to oral administration. In patients with
fluconazole and without azole co-medication, a 1:1.3 substitution is advised to prevent subtherapeutic CsA concentrations.
Keywords CyclosporineA . Immunosuppression .Hematopoietic stemcell transplantation .Dose conversion . FerdowsAtiq and
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Introduction
Cyclosporine A (CsA) is the most widely used immunosup-
pressive drug in the prevention and treatment of graft-versus-
host disease (GvHD) after hematopoietic stem cell transplan-
tation (HSCT) [1–4]. CsA is a narrow therapeutic index drug,
and blood levels are routinely monitored to maintain a thera-
peutic drug concentration [1, 5]. Suboptimal CsA concentra-
tions in the early period after HSCT are associated with a
higher incidence of acute GvHD [6]. Development of moder-
ate to severe GvHD is associated with higher early mortality
after HSCT [6]. The most relevant side effects of CsA are
nephro- and hepatotoxicity, which are correlated with high
CsA concentrations [2].
CsA is absorbed in the ileum and jejunum [1]. CsA has a
large inter- and intra-individual variability in bioavailability,
which depends on food intake, time since transplantation, liv-
er function, bile flow, genetics, and gastrointestinal state such
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as motility and length of the small intestine and diarrhea
(which can decrease the absorption of CsA) [1, 7].
In the early period after, HSCT patients can have a dam-
aged oral and gastrointestinal mucosa, especially after
myeloablative conditioning. Other patients experience diffi-
culty in swallowing tablets due to nausea after the condition-
ing regimen. In these patients, CsA is administered intrave-
nously to ensure that therapeutic concentrations are reached
[3]. As soon as patients tolerate oral intake, CsA is switched
from intravenous to oral administration [3]. The optimal con-
version rate from intravenous to oral administration is not
unambiguous due to differences in absorption and first pass
effect during oral administration [8]. Recommendations for
CsA conversion in HSCT patients from intravenous to oral
administration differ from a conversion rate of 1:1 to 1:3
[9–13]. However, recent studies recommend a conversion rate
of 1:2 from intravenous to oral administration [11–13].
CsA is a CYP3A4 and P-glycoprotein (P-gp) substrate and
may therefore be influenced by CYP3A4 and P-gp inhibitors
and inducers [1, 14]. Azole antifungals, which are commonly
used in the post-transplant period, increase CsA concentra-
tions by these mechanisms [15]. Azole antifungals can influ-
ence the bioavailability of CsA and therefore are likely to play
a role in the dose conversion of CsA. A study in four patients
found that concomitant use of voriconazole increased CsA
bioavailability, suggesting that a lower conversion rate from
intravenous to oral administration may be better in patients
taking oral voriconazole [13].
The aim of this study was to assess the optimal conversion
rate of CsA from intravenous to oral administration in HSCT
recipients, taking into account the concomitant use of different
azole antifungals.
Materials and methods
We retrospectively included patients from a large database of
483 patients who underwent a HSCT from 2008 until 2014 in
the Erasmus Medical Center. Patients receiving intravenous
CsA as part of the conditioning regimen and peritransplant
immunosuppression were included. Furthermore, at least one
conversion of CsA from the initial intravenous therapy to oral
administration had to be performed. The applied dose conver-
sion rate in all patients was 1:1. During both intravenous and
oral administration, CsA (Neoral®, Novartis) was adminis-
tered twice daily. CsA dosage was initiated based on patients’
weight. After measuring CsA concentrations, the CsA dose
was modified to remain within the therapeutic range.
To monitor the CsA concentration before and after the con-
version and to take the CsA intrapatient variability into ac-
count, we aimed to collect for each patient three CsA trough
concentrations during intravenous administration and three
trough concentrations during oral administration. The
collected concentrations were taken directly before and after
the conversion to oral administration. The CsA level was rou-
tinely measured 3 days/week, on Monday, Wednesday, and
Friday during hospital stay. After discharge from hospital,
CsA measurement was planned weekly. The CsA target level
was 250–350 ng/mL. The CsA assay was performed using a
validated UPLC-MS/MS method, routinely used in our clinic.
This method was developed in-house and validated according
to the FDA guidelines.
In our center, patients with an expected neutropenia
(granulocytes < 0.5 × 109/L) lasting longer than 10 days re-
ceived antimicrobial and antifungal drugs until neutrophil re-
covery. Antifungal drugs were preferred to be administered
orally. If patients could not tolerate oral intake, antifungal
drugs were administered intravenously. The standard antifun-
gal treatment was fluconazole 400 mg/day. Patients with a
history of invasive aspergillosis receive voriconazole as sec-
ondary prophylaxis, until immunosuppressive treatment is
discontinued.
In order to assess the influence of co-treatment with azole
antifungal drugs, patients were only included if the azole an-
tifungal was used during all CsA concentration measure-
ments. If a particular antifungal drug was used in less than
five patients, these patients were excluded.
All patients had signed informed consent at the time of
HSCT, which allowed for additional analyses on anonymized
data (such as the present retrospective analysis).
Clinical parameters
We assessed the influence of diarrhea and oral mucositis on
CsA concentrations. A patient was defined as having diarrhea
or mucositis when either of them was documented by physi-
cians during at least one of the CsA concentration measure-
ments. We also assessed the influence of CsA dose conversion
on renal function. The glomerular filtration rate (eGFR) was
calculated using the Modification of Diet in Renal Diseases
(MDRD) equation: eGFR (ml/min/1.73 m2) = 186 × (serum
creatinine (μmol/l) / 88.4) − 1.154 × age (in years)–0.203 ×
0.742 (for women) and multiplied by 1.21 for black patients.
Analysis
We categorized patients based on the use of concomitant azole
antifungal drugs. We calculated the dose-corrected CsA con-
centration for each measurement by dividing the CsA concen-
tration by the CsA dosage (daily dose) used at that time point.
The average dose-corrected CsA concentration was calculated
from the three concentrations measured for each patient dur-
ing intravenous and oral administration separately. The aver-
age CsA concentrations per patient during intravenous and
oral administration were normally distributed. Therefore, we
compared the mean calculated dose-corrected CsA
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concentrations between the intravenous and oral period for
each antifungal group by using a paired t test. We calculated
the bioavailability by dividing the mean dose-corrected CsA
concentration during oral administration by the mean dose-
corrected CsA concentration during intravenous administra-
tion. We compared groups by using an unpaired t test. We
used an unpaired t test for continuous baseline characteristics
and chi-square for categorical variables. We compared cate-
gorical variables between groups by using a chi-square test. A
p value below 0.05 was considered to be significant.
Results
We included 71 out of 483 transplanted patients. Figure 1
shows the reasons for exclusion. Most patients were excluded
because they were not treated with intravenous CsA. A second
reason for excluding patients was the lack of treatment with
azole antifungal drugs for the full period during which the
three intravenous and three oral CsA concentrations were ob-
tained. Posaconazole-treated patients were excluded from the
analysis due to insufficient numbers. One patient was excluded
because of unreliable CsA concentrations with a mean dose-
corrected CsA concentration that was exceptionally high (7.31
vs group mean of 2.05 ± 0.77). None of the included patients
used other co-medication which had an interaction with CsA.
Patient characteristics are presented for the total dataset and
for the three antifungal groups separately (Table 1). The mean
age was significantly higher in patients with fluconazole com-
pared to patients with voriconazole (p = 0.019) and patients
without azole co-medication (p = 0.035). No other differences
in baseline characteristics existed between the different
groups. Overall, the number of days between the first and
the last CsAmeasurement was significantly longer during oral
administration than during intravenous administration (p =
0.034). This is explained by discharge from the hospital and
less frequent measurements subsequently. Most patients were
diagnosed with acute myeloid leukemia (AML), followed by
myeloproliferative syndrome (MPS) (Table 2). All patients
received peripheral blood stem cells except for one patient in
the voriconazole group who received bone marrow-derived
stem cells. Seventy percent of patients received cord blood-
derived stem cells preceded by reduced intensity conditioning
(RIC), which consisted of a single administration of cyclo-
phosphamide followed by 4 days of fludarabine and 2 days
of total body irradiation (2 Gy TBI). Twenty-one percent of
patients had a matched unrelated donor (MUD) and 9% had a
sibling donor. Ten patients received myeloablative condition-
ing (MAC), consisting of high-dose cyclophosphamide and
2 × 6 Gy TBI or cyclophosphamide combined with busulfan.
Six patients received RIC, consisting of fludarabine and 2 Gy
TBI. Five patients received a conditioning regimen with high-
dose post-transplant cyclophosphamide. In almost all patients
(98%), fluconazole was administered once daily, whereas in
all patients, voriconazole was administered twice daily. The
mean daily fluconazole and voriconazole doses were respec-
tively 382 mg (± 7.92) and 457 mg (± 39.8).
In the total population, compared to intravenous CsA ad-
ministration, the mean CsA concentration was 20% lower
during oral administration (p < 0.001) (Fig. 2). In patients with
fluconazole and in patients without azole co-medication, the
mean CsA concentration was lower during oral administra-
tion, 19% (p < 0.001) and 31% (p = 0.014), respectively.
However, in patients with voriconazole co-treatment, there
was no difference in mean CsA concentrations during intra-
venous and oral administration (339.9 ± 24.5 vs 302.5 ±
29.0 ng/mL; p = 0.175). For the total of patients, there was
no difference in the mean CsA dosage during intravenous
and oral administration (175.4 mg ± 8.90 vs 171.5 mg ±
7.57, p = 0.476). In patients with fluconazole, voriconazole,
and without azole co-medication, the average CsA daily doses
during intravenous compared to oral administration were re-
spectively 170.6 mg ± 8.63 vs 174.5 mg ± 8.95 (p = 0.428),
134.1 mg ± 18.0 vs 117.5 mg ± 12.7 (p = 0.125), and
234.8 mg ± 33.7 vs 206.8 mg ± 16.7 (p = 0.300).
In all patients, the mean dose-corrected CsA concentration
was 18.5% (p < 0.001) lower during oral administration
(Fig. 3). In patients with voriconazole co-treatment, there
was no difference in dose-corrected CsA concentrations dur-
ing intravenous and oral administration (2.6% lower during
oral administration, p = 0.754), whereas in patients with flu-
conazole and without azole co-medication, the dose-corrected
CsA concentration was respectively 21.5% (p < 0.001) and
25.2% (p = 0.069) lower during oral administration. Patients
with fluconazole showed a similar trend as patients without
azole co-medication (Fig. 3); therefore, these patients were
grouped together.
CsA concentrations were often supratherapeutic during in-
travenous administration, while they were more often
Fig. 1 Consort diagram. HSCT hematopoietic stem cell transplantation,
IV1, IV2, IV3 first, second, last intravenous CsA administration before
dose conversion, PO1, PO2, PO3 first, second, third oral administration
after dose conversion
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subtherapeutic during oral administration (Fig. 4). The propor-
tion of patients with therapeutic CsA concentrations remained
nearly equal, while mean CsA concentrations decreased, indi-
cating a shift from high to low CsA concentrations.
Diarrhea and oral mucositis
In this series of patients, diarrhea was present in 14% of the
patients. The dose-corrected CsA concentration was not relat-
ed with the presence of diarrhea.
Oral mucositis was present in 22% of patients on flucona-
zole, in 40% of patients on voriconazole, and in 45% of pa-
tients without azole co-treatment. In patients on fluconazole,
the bioavailability was lower in patients with mucositis com-
pared to patients without mucositis (0.66 ± 0.06 vs 0.90 ±
0.05, p = 0.035). In patients on voriconazole and without azole
co-medication, there was no significant difference in the CsA
concentration between patients with and without oral
mucositis.
Renal function
The eGFR significantly decreased during intravenous and oral
administration (respectively with Δ9.2 ± 27.9 mL/min, p =
0.007 and Δ16.6 ± 29.9 mL/min, p < 0.001). There was no
difference in number of days between first and last creatinine
measurement (p = 0.168) during intravenous and oral admin-
istration (respectively 7.4 ± 1.7 and 8.1 ± 3.9 days). The de-
crease of eGFR was similar during intravenous and oral ad-
ministration (p = 0.088) (Fig. 5).
Discussion
In this study, we show that the bioavailability of CsA in HSCT
patients is remarkably high (75–80%), especially in patients
co-treated with voriconazole (almost 100%). This is quite sur-
prising compared to current available literature [11, 13–15]. In
our center, hematologists have used a 1:1 ratio for switching
CsA from intravenous to oral administration, and the data
shown in this paper support that strategy, especially for the
group of voriconazole co-treated patients [10]. In patients co-
treated with fluconazole and in patients without azole co-treat-
ment, a conversion rate of 1: 1.3 should allow for maintaining
stable CsA exposure. The CsA dose conversion did not influ-
ence the decrease of renal function caused by CsA
administration.
Our results are partially in accordance with earlier studies
in which the recommendation for dose conversion rate in
HSCT patients differed from 1:1 to 1:3. Nevertheless, there
Table 2 Patients diagnosis and treatment
Diagnosis Donor Conditioning
ALL AML CLL CML MDS MPS NHL PCL PLL SAA CB MUD Sib RIC MAC
Fluconazole 2 21 5 4 4 7 5 2 – – 74% 20% 6% 92% 8%
Voriconazole – 6 1 – 1 – – – 1 1 70% 20% 10% 70% 30%
No azole – 3 – 1 2 3 2 – – – 55% 27% 18% 73% 27%
Total 2 30 6 5 7 10 7 2 1 1 70% 21% 8% 86% 14%
ALL acute lymphatic leukemia, AML acute myeloid leukemia, CLL chronic lymphatic leukemia, CML chronic myeloid leukemia, MDS myeloid
dysplastic syndrome, MPS myeloproliferative syndrome, NHL non-Hodgkin lymphoma, PCL plasmacell leukemia, PLL prolymphocytic leukemia,
SAA severe aplastic anemia, CB cord blood, MUD matched unrelated donor, Sib sibling, RIC reduced intensity conditioning, MAC myeloablative
conditioning
Table 1 Patient characteristics
Patients Female Age (year) Weight (kg) Length (m) Number of days between
IV1-IV3 IV3-PO1 PO1-PO3
Fluconazole 50 18 (39%) 52 (22–70) 77 (53–107) 1.76 (1.51–1.96) 4.80* (3–7) 2.26 (1–4) 4.98* (3–7)
Voriconazole 10 4 (40%) 41 (19–65) 69 (58–94) 1.75 (1.59–1.95) 5.10** (4–7) 3.10 (1–8) 5.20** (4–9)
No azole 11 6 (55%) 43 (21–69) 75 (58–108) 1.75 (1.61–1.88) 4.73*** (4–5) 2.36 (2–4) 6.55*** (5–14)
Total 71 29 (41%) 49 (19–70) 76 (53–108) 1.76 (1.51–1.96) 4.83# (3–7) 2.39 (1–8) 5.25# (3–14)
Numbers are given as mean (range) or number (%)
IV1-IV3 first and last intravenous concentration, IV3-PO1 last intravenous and first oral administration, PO1-PO3 first and last oral administration
*p = 0.253; **p = 0.859; ***p = 0.056; #p = 0.034
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are major differences in study design and study subjects. Choi
et al. showed in 33 pediatric patients that CsA concentrations
remained in the therapeutic range with a conversion rate of 1:3
from intravenous to oral administration [9]. They found a
bioavailability of 0.43 during oral CsA administration.
However, this study was in children andmay not be applicable
to adults. Moreover, information on co-medication was limit-
ed. Parquet et al. showed in a randomized controlled trial in 14
patients comparing 1:1 with 1:2 conversion that the
converting rate of 1:2 tended to give more therapeutic CsA
concentrations in patients with concomitant use of fluconazole
[11]. Inoue et al. prospectively studied 11 patients that were
converted in a 1:2 ratio and found that the area under the curve
(AUC) remained nearly the same during intravenous and oral
administration [12]. Patients were co-treated with micafungin,
a non-azole antifungal agent, known to be a mild CYP3A4
inhibitor. The mean bioavailability of CsA during oral
administration was 0.58 ± 0.15. Kimura et al. investigated in
12 patients the conversion of CsA from continuous intrave-
nous administration to oral administration in a 1:2 conversion
rate [13]. AUC during oral administration was significantly
higher than the AUC during intravenous infusion (median
7508 vs 6705 ng/ml h, p = 0.050). The bioavailability of
CsA was 0.685 (range 0.45–1.04), but concomitant adminis-
tration of voriconazole (n = 4) significantly increased the bio-
availability of CsA (median 0.87 vs 0.54, p = 0.017). McGuire
et al. found in 52 patients with a dose conversion rate of 1:3
that the incidence of renal dysfunction during intravenous and
oral administration was respectively 29 and 63% (p = 0.0018)
[10]. Therefore, they suggested a dose conversion of 1:1 as
more appropriate to avoid renal dysfunction. However, they
did not measure CsA concentrations and it is not clear whether
the higher incidence of renal dysfunction was due to the CsA
conversion from intravenous to oral or because patients with
oral administration used CsA for a longer period of time.
Moreover, it is unclear whether the patients used azole
antifungals.
To summarize, the published studies on CsA dose conver-
sion included small numbers of patients and often did not take
the role of azole antifungals into account. These studies
showed that the bioavailability of CsA (Neoral®) in adults
ranged between 0.58 and 0.685, and therefore, a dose conver-
sion rate between 1:1 and 1:2 would be appropriate, as also
found in our study.
For voriconazole, which is a stronger CYP3A4 inhibitor,
the dose-corrected CsA concentration is nearly the same dur-
ing intravenous and oral administration, suggesting that
voriconazole co-treatment increases the oral bioavailability
of CsA to almost 100%. This is in accordance with the study
of Kimura et al. [13]. This is probably caused by inhibition of
CYP3A4 enzymes in the gut wall by voriconazole. This find-
ing was not observed in patients with fluconazole which is a
less potent CYP3A4 inhibitor [16].
The presence of mucositis resulted in a lower bioavailabil-
ity in patients co-treated with fluconazole, which may be
caused directly by a lower CsA absorption or indirectly by a
lower fluconazole absorption as shown earlier for
posaconazole [15]. There was no influence of mucositis on
CsA concentration in patients with voriconazole or without
azole co-medication, most likely due to the small number of
patients.
Strengths of our study are the large number of patients
compared to previous reports, the focus on the role of azole
antifungals on the CsA dose conversion, and the detailed rec-
ommendations we provide for dose conversion. A potential
limitation is the retrospective observational study design.
However, the medication data and laboratory measurements
were well documented in the patient files. Another potential
limitation is that we could not assess dose conversion during
use of other azole antifungals than voriconazole and
Fig. 2 Mean CsA concentration and dosage. Data are presented as mean
with 95% confidence interval. The dotted lines at 250 and 350 reflect the
therapeutic range of CsA. IV1, IV2, IV3 first, second, last intravenous
CsA administration before dose conversion, PO1, PO2, PO3 first, second,
third oral administration after dose conversion
Fig. 3 Mean dose-corrected CsA concentration. Each symbol reflects the
mean dose-corrected CsA concentration at the illustrated time point
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fluconazole. The dose conversion rate for other azole antifun-
gals could be extrapolated based on the degree of CYP3A4
inhibition of other azole antifungals. Ketoconazole,
itraconazole, and miconazole are known to be strong
CYP3A4 inhibitors and therefore CsA conversion with co-
treatment of these azoles may be comparable with CsA con-
version during voriconazole co-treatment [17]. We did not
calculate AUCs which would have made comparison with
earlier studies more reliable. However, for clinical use and
recommendations trough levels are the most important param-
eters of CsA pharmacokinetics. Furthermore, although our
total sample size is large compared to previous studies on
the dose conversion of CsA, the subgroups (i.e., voriconazole,
no azole co-medication) are rather small. However, we do not
think that our conclusion is influenced by the sample size,
because in patients co-treated with voriconazole, the differ-
ence in dose-corrected CsA concentration between intrave-
nous and oral administration was small (Fig. 3).
In conclusion, we found that CsA dose conversion from
intravenous to oral administration depends on co-treatment
with azole antifungal drugs. In patients co-treated with
voriconazole, the bioavailability of orally administered CsA
is almost 100%, and thus 1:1 conversion is best. During co-
treatment with fluconazole or without azole co-medication,
the CsA concentrations will drop with 20–25% after conver-
sion from intravenous to oral administration. Therefore, we
recommend a dose conversion rate of 1:1.3 in these patients.
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